The startup develops T-cell engaging therapies that enhance selectivity for tumor cells while ensuring robust T-cell activation, targeting a wide range of cancer types. This approach aims to improve patient safety and achieve more durable responses compared to traditional cancer treatments.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional cancer treatments often lack the precision needed to target tumor cells effectively, leading to significant side effects and limited efficacy. Existing therapies may not sufficiently activate the immune system to achieve durable responses across a broad spectrum of cancer types.
Solution
This startup is developing a novel class of T-cell engaging therapies designed to enhance the selective targeting of tumor cells while simultaneously ensuring robust T-cell activation. By improving selectivity, the therapies aim to minimize off-target effects and improve patient safety. The enhanced T-cell activation is intended to promote a more potent and sustained anti-tumor response, potentially leading to more durable remissions. The platform is engineered to be adaptable across a wide range of cancer types, addressing a significant unmet need in oncology.
Target Audience
The primary target audience includes oncology researchers, pharmaceutical companies, and ultimately, cancer patients seeking more effective and less toxic treatment options.
Features
- T-cell engagers designed for enhanced selectivity towards tumor-specific antigens
- Engineered to promote robust T-cell activation and proliferation within the tumor microenvironment
- Adaptable platform for targeting a wide range of cancer types and tumor-associated antigens